Purpose: To evaluate the outcome of 180° micropulse diode laser trabeculoplasty (MDLT) in patients with open-angle glaucoma.
Methods: A retrospective review of 40 eyes of 29 MDLT-treated patients with a minimum follow-up time of 6 months. Successful outcome was defined as follows: (i) a ≥20% or (ii) a ≥3-mmHg decrease of intraocular pressure (IOP), no further need for laser- or incisional surgery and the number of glaucoma medication was the same or less than preoperative. These definitions will from now on be referred to as definition one and definition two.
Results: Life-table analysis showed an overall success rate of 2.5% (1/40) and 7.5% (3/40) (according to definitions one and two, respectively) after up to 19 months of follow-up. The average time for failure was by definition one 2.9 months (standard deviation, SD ± 3.5, range 1-12 months) and by definition two 3.3 months (SD ± 3.9, range 1-16 months). There were no intra- or postoperative complications caused by MDLT. Postoperative inflammatory reaction, cells and flare, was scanty.
Conclusion: Our results suggest that 180° MDLT is a safe but ineffective treatment in patients with open-angle glaucoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1755-3768.2010.02026.x | DOI Listing |
Taiwan J Ophthalmol
January 2024
Foresight Eye Clinic, New Taipei City, Taiwan.
Purpose: This study aimed to explore the safety and efficacy of laser treatment settings of micropulse transscleral cyclophotocoagulation treatment in glaucoma patients and to evaluate the relationship between intraocular pressure (IOP) reduction and different treatment parameters.
Materials And Methods: A total of 74 eyes in 64 glaucoma patients with IOP over 21 mmHg or under 20 mmHg with visual field progression who underwent micropulse transscleral cyclophotocoagulation treatment were included. Patients were divided into success and failure groups based on criteria of 20% IOP reduction rate.
Arch Soc Esp Oftalmol (Engl Ed)
November 2024
Hospital General Universitario Reina Sofía, Murcia, Spain; Instituto Murciano de Investigación Biosanitaria (IMIB Virgen de la Arrixaca), El Palmar, Murcia, Spain; Red de Enfermedades Inflamatorias (Redes de Investigación Cooperativa Orientadas a Resultados en Salud [RICORS]); Departamento de Oftalmología, Facultad de Medicina, Universidad de Murcia, El Palmar, Murcia, Spain. Electronic address:
Cyclodestruction is a technique reserved for glaucomas not controlled with medical and surgical treatment and poor visual potential. During the last century, new cyclodestructive techniques were developed, including cyclophotocoagulation, and the use of continuous-wave diode laser transescleral cyclophotocoagulation (CW-TS-CPC) has become widespread. In recent decades, micropulse diode laser transescleral cyclophotocoagulation (MP-TS-CPC) was introduced.
View Article and Find Full Text PDFMed J Armed Forces India
February 2023
Professor (Ophthalmology), Command Hospital (Air Force), Bengaluru, India.
Background: The relative efficacy of 532 nm subthreshold micropulse laser in comparison to the 810 nm subthreshold micropulse laser, in the treatment of central serous chorioretinopathy is not known.
Methods: This randomized controlled trial included 99 eyes each in groups A and B. Key inclusion criteria were: (i) vision loss for minimum three months due to persistent central serous chorioretinopathy; (ii) focal leaks (upto two leaks) on fundus fluorescein angiography.
Arq Bras Oftalmol
August 2024
Department of Ophthalmology, Universidade de São Paulo, São Paulo, SP, Brazil.
Purpose: This study comparatively analyzed the morphology of eye tissues after laser exposure using the latest generation of transscleral laser techniques - micropulse transscleral cyclophotocoagulation (MP-TSCPC) and laser activation of scleral hydropermeability (LASH) - in an anatomical experiment.
Material And Methods: The study used pulsed-periodic radiation of an Er-glass fiber laser (λ=1.56 μm) and radiation of a diode laser (λ=0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!